Assessment of treatment options for patients with hepatitis C virus recombinant form 2k/1b

2020 ◽  
Author(s):  
Mamuka Zakalashvili ◽  
Jaba Zarkua ◽  
Robert G. Gish ◽  
Maia Zhamutashvili ◽  
Vakhtang Sartania ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Treatment Options ◽  
Recombinant Form ◽  
Virus Recombinant

Treatment outcomes of hepatitis C virus recombinant form 2k/1b with sofosbuvir based regimens in Georgia

2017 ◽  
Vol 66 (1) ◽  
pp. S302-S303
Author(s):  
M. Zakalashvili ◽  
J. Zarkua ◽  
M. Weizenegger ◽  
J. Bartel ◽  
M. Raabe ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Treatment Outcomes ◽  
Recombinant Form ◽  
Virus Recombinant

Impact of hepatitis C virus recombinant form RF1_2k/1b on treatment outcomes within the Georgian national hepatitis C elimination program

2017 ◽  
Vol 48 (1) ◽  
pp. 36-44 ◽  
Author(s):  
Marine Karchava ◽  
Nikoloz Chkhartishvili ◽  
Lali Sharvadze ◽  
Akaki Abutidze ◽  
Natia Dvali ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Treatment Outcomes ◽  
Recombinant Form ◽  
Virus Recombinant

New treatment options of chronic hepatitis C virus infection

2011 ◽  
Vol 152 (22) ◽  
pp. 887-897 ◽  
Author(s):  
Béla Hunyady
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Rapid Development ◽  
Treatment Options ◽  
Treatment Success ◽  
Hepatocellular Cancer ◽  
Hepatic Decompensation ◽  
Chronic Hepatitis C Virus

Chronic hepatitis C virus (HCV) infection is the major etiology and the reason of chronic liver disease, liver cirrhosis, hepatic decompensation, hepatocellular cancer and liver transplantation. Less than half of patients with HCV-related chronic hepatitis achieve sustained viral clearance with current pegylated interferon and ribavirin (P+R) combination therapy. Due to the insufficient treatment success, an extended search for new, direct acting anti-HCV agents (DAAs) is ongoing, already leading to submissions of applications for marketing authorization of the protease-inhibitors boceprevir and telaprevir. Both are effective only in triple combinations with P+R. Studies demonstrate a 50% success rate advantage for triple therapies above current standards. In addition, treatment duration can be shortened, and half of the patients who failed previous therapy with P+R can be cured with triple therapies. A major concern with new DAAs is rapid development of DAA-resistant viral mutants, a reason as well as a consequence of insufficient triple therapy. Clinical studies with boceprevir and telaprevir are reviewed in this paper. Orv. Hetil., 2011, 152, 887–897.

scholarly journals First identification of a recombinant form of hepatitis C virus in Austrian patients by full-genome next generation sequencing

PLoS ONE ◽  
2017 ◽  
Vol 12 (7) ◽  
pp. e0181273 ◽  
Author(s):  
Evelyn Stelzl ◽  
Bernhard Haas ◽  
Bernd Bauer ◽  
Sherry Zhang ◽  
Ellen H. Fiss ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Next Generation Sequencing ◽  
Recombinant Form ◽  
Full Genome ◽  
Next Generation ◽  
Generation Sequencing
Sign in / Sign up

Export Citation Format

Share Document